Category: AI & ML
-
Structure-based and generative drug design in the clinic: elegant molecules, but whose efficacy?
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. The 30-second version What. Structure-based and generative design engines (Insilico’s Chemistry42, Isomorphic’s IsoDDE, Schrödinger’s FEP+, Relay’s motion-based platform) have demonstrably done one thing: designed and optimized molecules well enough to enter the clinic,…
-
Recursion and Exscientia: the phenotypic engine can discover, but the clinic has not confirmed it
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. The 30-second version What. Recursion’s phenotypic engine (Recursion OS, a phenomics data universe of more than 25 petabytes) has demonstrated a real capability: to surface candidates from cellular phenotypes without knowing the target…
-
The landscape of AI drug-discovery platforms: the design is proven, but is the clinic?
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. The 30-second version What. AI drug-discovery platforms (Recursion, Insilico, Isomorphic, Schrödinger, Relay, Nimbus and others) have partly proven that they can design and optimize molecules — many candidates have entered the clinic and…
